Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 6/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ESRRG | P62508 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25848829 | 0.88 | HDAC3 (0.40) | AKT3HDAC3HDAC1HDAC4HDAC6 | |
| SCHEMBL25262077 | 0.86 | HDAC1 (0.43) | AKT3HDAC3HDAC1HDAC4HDAC6 | |
| SCHEMBL25848775 | 0.83 | MEN1 (0.52) | KMT2AMEN1TDP1KDM4EALDH1A1 | |
| SCHEMBL25848928 | 0.82 | CA1 (0.46) | AKT3HDAC3HDAC1HDAC4HDAC6 | |
| SCHEMBL25848884 | 0.82 | CCR1 (0.47) | HDAC3HDAC1HDAC4HDAC6KMT2A | |
| SCHEMBL25848805 | 0.81 | USP5 (0.46) | AKT3HDAC3HDAC1HDAC4HDAC6 | |
| SCHEMBL25848828 | 0.80 | EPHX2 (0.53) | HDAC3HDAC6KMT2AMEN1LMNA | |
| SCHEMBL25848782 | 0.80 | KMT2A (0.49) | AKT3HDAC3HDAC1HDAC4HDAC6 | |
| SCHEMBL25304098 | 0.79 | EPHX2 (0.48) | HDAC3HDAC1HDAC4HDAC6NAMPT | |
| SCHEMBL25849324 | 0.79 | PPARA (0.49) | HDAC3HDAC1HDAC4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219921-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219921-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | AKT3 2460/4885HDAC3 1223/4885HDAC1 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.